Please login to the form below

Not currently logged in
Email:
Password:

Warp Drive Bio names Gregory Verdine as CEO

Joined by James Nichols as chief operating officer and new board member Julian Adams

Warp Drive Bio Gregory Verdine Genomics firm Warp Drive Bio has named its co-founder Gregory Verdine as CEO.

He replaces founding CEO Alexis Brosy who is set to become executive chairman of the Cambridge, US-based company.

In addition to this succession, Warp Drive Bio announced that Dr James Nichols will join the company as chief operating officer and Dr Julian Adams will join the board of directors.

The reorganisation is part of Warp Drive Bio's plans to advance its programmes of genomic technologies to discover natural-source drugs, as part of which it has a £125m partnership with Sanofi.

“Today, this is underscored by the appointment of three proven, renowned and tenacious drug discovery and development experts to our team,” said departing CEO Borisy.

His replacement Dr Verdine helped launch the company in 2012 after an entrepreneurial career that included co-founding several biotech companies, including Enanta Pharmaceuticals, Gloucester Pharmaceuticals, Aileron Therapeutics, Tokai Pharmaceuticals, Ontorii Pharmaceuticals and Eleven Biotherapeutics.

He has also served as a global consultant for Roche, scientific adviser to Vertex and Ariad, and currently sits on the boards of the US National Cancer Institute and the SMA Foundation.

“The research being conducted by the Warp Drive Bio team is one of the most exciting scientific enterprises that I have ever been a part of, and I am thrilled to lead the company as we enter our next phase of growth and progress,” he said.

Dr Nichols joins as chief operating officer from Resolvyx Pharmaceuticals, where he was president and chief operating officer.

Dr Adams is president of R&D at Infinity Pharmaceuticals having served at Millennium Pharmaceuticals, where he had global responsibility for multiple drug discovery programmes, including the successful discovery and development of cancer treatment Velcade (bortezomib).

4th July 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics